9/10/2019 – Co-Founder & Executive Director, David Fajgenbaum, releases a memoir about his life-threatening battle with Castleman disease and the CDCN’s story—now available wherever books are sold!
8/26/2019 – Dr. David Fajgenbaum, co-Founder & Executive Director of the Castleman Disease Collaborative Network (CDCN), a physician-scientist at the University of Pennsylvania, and a patient battling the same disease that he studies, were profiled today on Good Morning America as part of a segment about Fajgenbaum’s new book, Chasing My Cure: A Doctor’s Race to Turn Hope Into Action
7/26/2019 – A clinical trial to evaluate the medication sirolimus for treatment-refractory idiopathic multicentric Castleman disease is launching in Summer 2019! The trial is run by the University of Pennsylvania and the University of Arkansas for Medical Sciences.
7/19/2019 – The Philadelphia City Council unanimously passed a resolution declaring July 23 as World Castleman Disease Day in the City of Philadelphia! This resolution not only recognizes the CDCN’s celebration of the 2nd annual World Castleman Disease Day, but also shows the council’s support in the the continued efforts of the CDCN to accelerate research to find a cure for Castleman Disease and improve the lives of all Castleman patients and their loved ones.
7/17/2019 – Recent research from physicians in the CDCN network has uncovered a gene that is mutated in the lymph node cells of some UCD patients!
6/11/2019 – The Castleman Disease Collaborative Network (CDCN) is excited to announce that we are partnering with the Chan Zuckerberg Initiative (CZI) to accelerate Castleman disease research and further build a prototype that revolutionizes all rare disease research.
6/11/2019 PHILADELPHIA (June 2019) — The Castleman Disease Collaborative Network (CDCN) is proud to announce a new partnership with the Chan Zuckerberg Initiative (CZI) to strengthen and scale the CDCN’s collaborative network approach to advance cures for CDCN and other rare diseases. CDCN’s model inspired CZI’s Rare As One Project, committed to uniting rare disease communities in their quest for cures.
5/3/2019 – Thanks to a study funded by the CDCN’s Castleman Disease Warriors, the Wharton Class of 2015, and the Penn Orphan Disease Center, the first whole genome sequencing of Castleman patients was carried out by Dr. Minji Byun! Dr. Minji Byun, an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai, conducted a research study which had the goal of seeing if a possible cause of CD could be a genetic defect.
4/18/2019 – CDCN leaders David Fajgenbaum (Co-Founder), Mary Zuccato (COO), and Dustin Shilling (Senior Scientific Advisor) published “The Collaborative Network Approach: A model for advancing patient-centric research for Castleman disease and other rare diseases” in a 2019 review article in the journal Emerging Topics in Life Sciences. This paper outlines the CDCN’s novel strategy to accelerate research and reach the goal of finding an effective treatment for all Castleman disease patients.
12/21/2018 – 2018 has been an amazing year for the CDCN! In honor of all the progress that we have recently made thanks to support of hundreds of patients, loved ones, and community members from around the world, we are highlighting some of our biggest accomplishments of 2018.
12/18/2018 – The Castleman Disease Collaborative Network (CDCN) is excited to announce the recent publication of a study that identified key laboratory markers that help to predict whether patients with idiopathic multicentric Castleman disease (iMCD) will respond to siltuximab.
12/18/2018 – The Fourth Annual Quest for a Cure Gala was an incredible success! Quest for a Cure was held on November 16, 2018 at the beautiful Arts Ballroom in Philadelphia, PA. Our CDCN community of patients, loved ones, and supporters came together for a beautiful evening filled with cocktails, hoeur d’oeuvres, a seated dinner, and a silent auction.
12/7/2018 – The Castleman Disease Collaborative Network had its best showing yet at the American Society of Hematology’s Annual Meeting and Exposition, the premier event of the global hematology community! This year, ASH’s annual meeting brought together over 27,000 researchers, physicians, and educators from all over the world, including many of the world’s foremost experts in Castleman disease.
12/8/2018 – The 2018 Patient and Loved One Summit was a hit! The fifth annual summit took place on September 21-22, 2018 at the University of Pennsylvania and brought together over 90 patients, loved ones, and CDCN volunteers and staff from around the world.
9/28/2018 – The CDCN convened 42 experts from 10 different countries to establish the first-ever treatment guidelines for idiopathic (HHV-8-negative) multicentric Castleman Disease (iMCD) based on data from over 300 iMCD patients.
8/13/2018 – A new French reference center for Castleman disease held a launch meeting in Paris, “Premiere Journee du Centre de Référence ‘Maladie de Castleman!” The meeting was led by the Director of the new Center, Dr. Eric Oksenhendler. Dr. Oksenhendler has spent over 20 years pushing the Castleman disease field forward, including a large case series from as far back as 1996 that highlighted the significant morbidity and mortality associated with multicentric Castleman disease at the time.
6/20/2018 – We are proud to announce the publication of our SPEED I (Serum Proteomics Evaluation for Etiology and Pathogenesis Data I) research study in the American Journal of Hematology in April 2018 titled Plasma proteomics identifies a ‘‘chemokine storm’’ in idiopathic multicentric Castleman disease. The study found that iMCD is not simply a disorder of IL-6; it’s a complex inflammatory disorder that the global medical community is just beginning to unravel.
2/28/2017 – Big strides were made recently for the diagnosis of Castleman disease patients! The first-ever diagnostic criteria for HHV-8-negative “idiopathic” Multicentric Castleman disease has been published in the top hematology journal, Blood. Though Castleman disease was first described in 1954, this is the first time there has ever been a diagnostic criteria for it.
1/7/2015 – Dr. David Fajgenbaum, co-Founder & Executive Director of the CDCN and Adjunct Assistant Professor of Medicine in the division of Hematology/Oncology at the University of Pennsylvania, was named to Forbes Magazine’s 30 Under 30 list in healthcare! Dr. Fajgenbaum is a physician-researcher-entrepreneur that has repeatedly used personal adversity as motivation to create groundbreaking initiatives that overcome serious problems.